April 6 (Reuters) - Incyte Corp :
* LILLY AND INCYTE COMMUNICATE REVIEW EXTENSION OF SUPPLEMENTAL NEW DRUG APPLICATION FOR BARICITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS
* INCYTE CORP - PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE HAS BEEN EXTENDED THREE MONTHS TO EARLY Q3 2021.
* INCYTE CORP - FDA EXTENDED ACTION DATE TO ALLOW TIME TO REVIEW ADDITIONAL DATA ANALYSES SUBMITTED BY LILLY IN RESPONSE TO RECENT INFORMATION REQUESTS
* INCYTE CORP - EXTENSION DOES NOT AFFECT LILLY'S PREVIOUSLY-ISSUED FINANCIAL GUIDANCE FOR 2021
Source text for Eikon: Further company coverage:
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com)
* LILLY AND INCYTE COMMUNICATE REVIEW EXTENSION OF SUPPLEMENTAL NEW DRUG APPLICATION FOR BARICITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS
* INCYTE CORP - PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE HAS BEEN EXTENDED THREE MONTHS TO EARLY Q3 2021.
* INCYTE CORP - FDA EXTENDED ACTION DATE TO ALLOW TIME TO REVIEW ADDITIONAL DATA ANALYSES SUBMITTED BY LILLY IN RESPONSE TO RECENT INFORMATION REQUESTS
* INCYTE CORP - EXTENSION DOES NOT AFFECT LILLY'S PREVIOUSLY-ISSUED FINANCIAL GUIDANCE FOR 2021
Source text for Eikon: Further company coverage:
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com)